MULTIDRUG RESISTANCE IN ACUTE-LEUKEMIA - A CONSERVED PHYSIOLOGICAL-FUNCTION

被引：9

作者：

LIST, AF

SPIER, CM

机构：

[1] Sections of Hematology/Oncology and Bone Marrow Transplantation, Department of Internal Medicine and Department of Pathology, University of Arizona, College of Medicine, Tucson, AZ

来源：

LEUKEMIA & LYMPHOMA | 1992年 / 8卷 / 1-2期

关键词：

MDR; ACUTE LEUKEMIA; MULTIDRUG RESISTANCE;

D O I：

10.3109/10428199209049812

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Native resistance to conventional chemotherapy remains an important cause of treatment failure in the adult acute leukemias. Delineation of cellular mechanisms of drug resistance therefore represents a prerequisite to the development of more effective treatment strategies. The multidrug resistance (MDR) phenotype represents one such mechanism of resistance with direct clinical relevance. This phenotype occurs normally in certain mammalian tissues, and is detectable in tumor cell lines selected for resistance to naturally occurring antineoplastics. The mdr1 gene or its glycoprotein product, P-glycoprotein, is detected with high frequency in secondary acute myeloid leukemia (AML) and poor-risk subsets of acute lymphoblastic leukemia. In prospective studies in AML, MDR overexpression is an independent determinant of response to treatment and overall survival with conventional-dose induction regimens. Investigations of mdr1 regulation in normal hematopoietic elements has shown a pattern which corresponds to its regulation in acute leukemia, explaining the linkage of mdr1 to specific cellular phenotypes. Therapeutic trials are now in progress to test the ability of various MDR-reversal agents to restore chemotherapy sensitivity in high-risk acute leukemias.

引用

页码：9 / 14

页数：6

共 58 条

[1]

Cancer Genet. Cytogenet., 2, pp. 108-113, (1979)

[2]

Bloomfield C.D., De La Chapelle A., Chromosome abnormalities in acute nonlymphocytic leukemia: Clinical and biological significance, Semin. One, 14, pp. 372-383, (1987)

[3]

Correlation of karyotype and occupational exposure to potential mutagenic/carcinogenic agents in acute nonlymphocytic leukemia, Cancer Genet. Cytogenet., 11, pp. 326-332, (1982)

[4]

Geller R.B., Zahurak M., Hurwitz C.A., Et al., Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: The significance of the stem-cell glycoprotein CD34 (MylO), Br. J. Haematol, 76, pp. 340-347, (1990)

[5]

Amadori S., Pett M.C., De Francesco A., Et al., Lack of prognostic significance of the pretreatment labelling and mitotic indices of marrow blasts in acute nonlymphocytic leukemia (ANLL), Cancer, 41, pp. 1154-1160

[6]

Maddox A.M., Johnston D.A., Barlogie B., Youness E., Keating M., Freireich E.J., DNA-RNA measurements in patients with acute leukemia undergoing remission induction therapy, J. Clin. Oncol, 3, pp. 799-808, (1985)

[7]

Pastan I., Gottesman M., Multidrug resistance in human cancer, N. Engl. J. Med, 316, pp. 1388-1393, (1979)

[8]

Gros P., Ben-Neriah Y., Croop J., Housman D.E., Isolation and expression of a cDNA (mdr) that confers multidrug resistance, Nature, 323, pp. 728-731, (1986)

[9]

Ueda K., Cardalelli C., Gottesman M.M., Pastan I., Expression of a full-length cDNA for the human mdr 1 gene confers resistance to colchicine, doxorubicin, and vinblastine, Proc. Natl. Acad. Sci. USA, 84, pp. 3004-3008, (1987)

[10]

Callan D.F., Baker E., Simmers R.N., Seshardri R., Roninson I.B., Localization of the human multiple drug resistance gene, mdr 1, to 7q21.1, Human Genet., 77, pp. 142-144, (1987)

← 1 2 3 4 5 6 →